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The	 Integrated	 Stress	 Response	 (ISR)	 is	 a	 conserved	 translational	 and	 transcriptional	
program	affecting	metabolism,	memory	and	immunity.	The	ISR	is	mediated	by	stress-
induced	phosphorylation	of	translation	initiation	factor	2α	(eIF2α)	that	attenuates	the	
guanine	 nucleotide	 exchange	 factor	 eIF2B.	 A	 chemical	 inhibitor	 of	 the	 ISR,	 ISRIB,	
reverses	 the	 attenuation	 of	 eIF2B	 by	 phosphorylated	 eIF2α,	 protecting	 mice	 from	
neurodegeneration	 and	 traumatic	 brain	 injury.	We	 describe	 a	 4.1	 Å	 resolution	 cryo-
electron	microscopy	 structure	 of	 human	 eIF2B	with	 an	 ISRIB	molecule	 bound	 at	 the	
interface	between	the	β	and	δ	regulatory	subunits.	Mutagenesis	of	residues	lining	this	




















added	 a	 fluorescently	 labeled	 derivative	 of	 ISRIB	 (AAA2-101)	 (Fig.	 S2A)	 to	 purified	
eIF2B	 and	 observed	 increased	 fluorescence	 polarization	 (FP)	 (Fig.	 1A-left	 panel).	
Unlabeled	 ISRIB	 competed	 for	 eIF2B	 in	 the	 FP	 assay	with	 an	 EC50	 in	 the	 nanomolar	
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Materials and Methods 
Cell culturing and reagents 
The HeLa-derived cell line was maintained in DMEM Joklik modification 
(M0518, Sigma) supplemented with 0.2% NaHCO3 (S8761, Sigma), Newborn Calf 
Serum (N4637, Sigma), 1x Penicillin/Streptomycin (P0781, Sigma), 1x non-essential 
amino acid solution (M7145, Sigma), and 55 µM β-mercaptothanol. Suspension 
cultures were grown in either Erlenmeyer flasks in a Minitron shaker (Infors HT) at a 
shaking speed 70 rpm, 37°C, 8% CO2, or in a Cellbag (BC10, GE Healthcare) using a 
WAVE Bioreactor 20/50 EHT system (GE Healthcare) at 37°C, 8% CO2, air flow 0.3 
sp, angle 5°-7.5°, rotation speed 15-18.5 rpm. 
CHO-K1-derived cell lines were maintained either in Nutrient Mixture F12 
(N4888, Sigma), 10% Fetal Calf serum (FetalClone II, Thermo), 2 mM L-glutamine, 
and 1x Penicillin/Streptomycin at 37°C with 5% CO2 for adherent cells or in MEM 
Alpha (M8042, Sigma) with 10% Fetal Calf serum, 2 mM L-glutamine, 1x 
Penicillin/Streptomycin, 1x non-essential amino acid solution, and 55 µM β-
mercaptothanol in Erlenmeyer flasks in Minitron shaker (Infors HT) at a shaking 
speed 70 rpm, 37°C, 8% CO2 for suspension cells. 
 
Sucrose Gradient 
75x106 cells (in 75 mL) of HeLa-2C2 (3xFLAG-EIF2B2 in/in) cell suspension 
were treated for 20 minutes with either 150 µL DMSO or 200 nM ISRIB, prior to 
harvesting and lysing in 3x cell pellet volume of the lysis buffer [50 mM Tris (pH 
7.4), 400 mM KCl, 4 mM Mg(OAc)2, 0.5% Triton, 5% Sucrose, 1 mM DTT, 2 mM 
PMSF, 10 µg/ml Aprotinin, 4 µg/µl Pepstatin, 4 µM Leupeptin]. Lysates were cleared 
at 21,130 g in a chilled centrifuge, 0.5 mL of the supernatant was applied on 5mL of 
5-20% Sucrose gradient, that was prepared on SG15 Hoeffer Gradient maker in the 
cell lysis buffer with respective amounts of sucrose and equilibrated for 24 hours on 
ice. Velocity gradient centrifugation was on a SW50.1 rotor at 40,000 rpm for 14 
hours and 20 minutes and the gradient was divided into 13 fractions of 420 µL. Each 
fraction was then diluted two-fold with lysis buffer without sucrose, proteins were 
precipitated with 20% TCA for 16 hours at 4℃ and pelleted at 21,130 g for 20 
minutes in a chilled centrifuge. Protein pellets were washed twice with ice-cold 
acetone, air-dried, resuspended in 60 µL of alkaline SDS loading buffer and 5 µL of 
resuspension was resolved on a 12.5% SDS-PAGE gel. The protein gel was then 
transferred onto PVDF membrane and immunoblotted, using primary monoclonal 
mouse anti-FLAG M2 antibody (F1804, Sigma) and secondary polyclonal goat anti-
mouse-IR800, followed by scanning on Odyssey imager (LI-COR Biosciences) and 
image analysis on ImageJ software. 
 
Protein purification 
Human eIF2B was purified from 50 L of HeLa-2C2 cells (3xFLAG-EIF2B2 
in/in) grown in suspension at a maximum density of 106 cells/mL. Cell pellets (150 
grams total) were harvested at room temperature and washed twice with room 
temperature PBS. Cells were then lysed in 2 pellet volumes of lysis buffer [50 mM 
Tris (pH 7.4), 150 mM NaCl, 0.5% Triton, 10% Glycerol, 5 mM MgCl2, 1 mM DTT, 





structural analysis lysis buffer was supplemented with 200 nM ISRIB. Lysates were 
cleared at 20,000 rpm (JA 25.50) at 4℃ and supernatants were incubated with 5 mL 
of anti-FLAG M2 affinity gel (A2220, Sigma) for one hour at 4℃. The resin with 
bound eIF2B was washed three times for 5 minutes with 10 mL of ice-cold lysis 
buffer containing 500 mM NaCl, then washed three times for 5 minutes with 10 mL 
of washing buffer [50 mM Tris (pH 7.4), 150 mM NaCl, 0.1% CHAPS, 5m M MgCl2, 
1 mM DTT]. The bound protein was eluted twice sequentially in 10 mL of the 
washing buffer supplemented with 150 mg/mL 3X FLAG peptide (F4799, Sigma), 
concentrated to 2 mg/mL using 100K MWCO PES concentrator (88503, Pierce) and 
100 µL of concentrated protein complex was size fractionated on a SEC-3 300 Å 
HPLC column (P.N. 5190-2513, Agilent) at a flow rate of 0.35 mL/min in gel 
filtration buffer [50 mM Tris (pH 7.4), 150 mM NaCl, 5 mM MgCl2, 1 mM DTT]. 
The centre of the 280 nm absorbance peak eluting around 6 minutes was collected in 
42 µL and then applied onto cryo-grids for subsequent cryo-electron microscopy 
imaging. For the fluorescence polarization experiments the concentrated FLAG-M2 
eluate was used. 
Hamster eIF2B from CHO-S7 [Eif2b3-3xFLAG in/in; Eif2b4wt], CHO-S9 
[Eif2b3-3xFLAG in/in; Eif2b4L180F in/Δ] or CHO-B3 [Eif2b3-3xFLAG in/in; 
Eif2b2H188K in/ Δ] was purified as human eIF2B (above) (16), with following 
modifications: Hamster eIF2Bwt cells were harvested from 3.5 L of CHO-S7 
suspension culture grown at maximum density of 106 cells/mL, washed with room 
temperature PBS and lysed in two pellet volumes of lysis buffer. Cleared lysate 
supernatant was incubated with 300 µL of anti-FLAG M2 affinity gel. The resin was 
washed three times for 5 minutes with 1 mL of lysis buffer containing 500 mM NaCl, 
then washed three times for 5 minutes with 1 mL of washing buffer [50 mM Tris 
(pH7.4), 150 mM NaCl, 2 mM MgCl2, 0.01% Triton, 1 mM DTT]. Protein was eluted 
in two resin volumes of washing buffer supplemented with 125 mg/mL 3X FLAG 
peptide. Hamster eIF2BδL180F along with eIF2BβH188K mutant cells (with total cell 
count of 50x107 each) were harvested and washed with room temperature PBS, then 
lysed in three pellet volumes of lysis buffer. Cleared lysate supernatant was incubated 
with 60 µL of anti-FLAG M2 affinity gel following binding, washing and eluting 
procedures as described above. 
 
Fluorescence polarization assay 
20 µL reactions were assembled in 384-well round bottom polystyrene plates 
(3677, Corning), equilibrated in the assay buffer [50 mM Tris (pH7.4), 150 mM 
NaCl, 2 mM MgCl2, 0.01% Triton, 1 mM DTT] for 10 minutes at room temperature 
and either read directly or read 25 minutes after addition of unlabeled competitor on a 
CLARIOstar microplate reader (BMG Labtech) with filter settings of 482 nm 
(excitation) and 530 nm (emission). The fluorescein-labeled AAA2-101 compound 
was used in the range of 1-100 nM with corresponding amounts of purified eIF2B of 
30-250 nM. Each measurement point was either an average of six readings every 30 
seconds (for eIF2B dose-response) or five readings every 60 seconds (for unlabeled 
competitor assay). 
Binding of the fluorescent probe to eIF2B in the competition experiments was 
expressed as a fraction of relative polarization signal (%P) over the dynamic range of 
the assay. Relative polarization was calculated by subtracting background FP (Pbg) 





eIF2B was added and the maximal FP (Pmax) with eIF2B alone (in the presence of 
probe and in absence of non-fluorescent competitor compounds) define the dynamic 
range of the assay. Values of relative polarization for any assay point (%Pn) were 
calculated using the formula %Pn=(Pn-Pmin)/Pmax-Pmin)*100). 
 
Measuring ISRIB action in cultured cells: 
ISRIB action was tracked by its effects on the activity of a stably-integrated 
ISR-responsive CHOP::GFP reporter gene in CHO-K1 cells, as described previously 
(8). Inhibition of histidyl-tRNA synthetase by histidinol activates the eIF2α kinase 
GCN2 that phosphorylates eIF2. eIF2(αP) inhibits the GEF eIF2B, initiating the ISR 
and culminating in CHOP::GFP activation, which is detected by fluorescent activated 
cell sorting (FACS). In wildtype, ISRIB-sensitive cells the presence of ISRIB 
attenuates the response of the CHOP::GFP reporter, whereas in ISRIB resistant, 
mutant cells, the CHOP::GFP reporter remains active despite ISRIB’s presence. 
40 x 103 CHO-K1 derivatives carrying a stable CHOP::GFP reporter transgene 
were plated in 6 well plates. Two days later the culture medium was replaced with 2 
mL of fresh medium and compounds added. Immediately before analysis, the cells 
were washed with PBS and collected in PBS containing 4 mM EDTA. Single cell 
fluorescent signals (10,000/sample) measured by FACS Calibur (Beckton Dickinson). 
FlowJo software was used to analyze the data. 
 
Generation of the genome edited cells with altered ISRIB responsiveness by 
CRISPR/Cas9 
The genotypes and descriptions of the cell lines is provided in table S1. 
Cell lines HeLa-2C2 cells [3xFLAG-EIF2B2 in/in] and CHO-S7 [Eif2b3-
3xFLAG in/+; Eif2b4wt] have been previously described (8, 16).  
 To generate CHO-S9 [Eif2b3-3xFLAG in/in; Eif2b4L180F in/Δ] a 3xFLAG tag 
was incorporated into the Eif2b3 gene of CHO-C30 [Eif2b4L180F in/Δ] cells at the C-
terminus of eIF2Bγ subunit by a CRISPR/Cas9 mediated homology-directed repair 
following a published procedure (16). In brief, CHO-C30 [Eif2b4L180F in/Δ] cells were 
plated in 6-well plates at a density of 2 x 105 per well. 24 hours later the cells were 
transfected with the repair template plasmid (1 µg) and an sgRNA/Cas9 plasmid (1 
µg) using Lipofectamine LTX (Invitrogen) according to manufacturer’s instruction. 
The next day, GFP positive cells, which indicate plasmid-transfected cells, were 
collected using a Beckman Coulter MoFlo Cell sorter, and expanded as single clones 
in 96 well plates. Genomic DNAs isolated from the clones were screened and 
sequenced to confirm the insertion. Cells from clone S9 were then used to purify 
endogenous γ-3xFLAG-tagged eIF2B. 
Site-directed random mutagenesis of hamster Eif2b2 was carried out using 
CRISPR/Cas9 homologous repair using an equimolar mixture of single-stranded oligo 
deoxynucleotides (ssODN) as repair templates containing combination of all possible 
codons (n=64) for each targeted site proving the diversity of substitutions (Scheme 
S1). Each set of ssODNs was transfected along with a sgRNA guide, inserted into a 
vector containing mCherry marked Cas9, in the following pairs: UK2105 with 
ssODN-1922 or ssODN-1923, UK2106 with ssODN-1924 (see tables S2, S3 for 






Scheme S1. CRISPR/Cas9 directed mutagenesis of the hamster Eif2b2 gene at 
the locus encoding ISRIB contact sites on the eIF2B β subunit revealed by the 
structure: N162, H188 or I190. Hamster Eif2b2 exon 3 with the two RNA guides, 
directing Cas9 to mediate double strand break, and the aligned single-strand repair 
templates. The randomized substitution of the original codon is indicated (NNN), as 
are the silent PAM-disrupting mutations. Nucleotide numbering corresponds to 
GeneBank accession NW_003613913.1. 
For transfection 20 x 103 CHO-S7 cells (derivatives of CHO-K1 bearing 
3xFLAG-tagged Eif2b3) (16) were plated 36 hours prior being transfected with equal 
amounts of 1 µg guide and 1 µg ssODN using standard Lipofectamine protocol, 
expanded and sorted 48 hours later (Scheme S2). Before sorting for ISRIB resistance 
or sensitivity a technical “mCherry-positive” sort for successfully transfected cells 
was done and 240K, 360K and 330K cells were collected for N162X, H188X and 
I190X templates respectively. Five days later the recovered cell pools were treated 
with 0.5 mM histidinol (22883, Acros) and 200 nM ISRIB. 20 hours later pools were 
sorted for “GFP-bright” (ISRIB-resistant) and “GFP-dull” (ISRIB-sensitive) 
phenotypes (Sort I, scheme S2). 37K, 126K and 240K cells for each of respective 
ISRIB-resistant pools: N162X, H188X and I190X, and 500K for each of ISRIB-
sensitive pools were collected. 10 days later “GFP-dull” sort of untreated pools (Sort 
II, scheme S2) was carried out, to eliminate clones with a constitutively active ISR. 
1X106 cells were collected for each of ISRIB-resistant and ISRIB-sensitive pools.  
 
Scheme S2. Selection of ISRIB-sensitive (ISRIBSEN) and ISRIB-resistant (ISRIBRES) 
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CRISPR/Cas9 mutagenesis, based on the ISR-activated CHOP::GFP fluorescent 
reporter upon histidinol (HIS) treatment of CHO-K1 cells. 
 
For a new round of sorting to reselect analog-sensitive pools from ISRIB-
resistant Eif2bH188X pool (Scheme S3), 1 x 106 cells were plated 36 hours before being 
treated with 0.5 mM histidinol and 2.5 µM of ISRIB or 2.5 µM ISRIB analog 
(AAA1-075B or AAA1-084). 20 hours later cells were sorted for “GFP-dull” (analog-
sensitive) phenotype, and 1 x 106 cells were collected for each respective pool 
(ISRIB-sensitive, 075B-sensitive and 084-sensitive). Note that a newly selected 
ISRIB-resistant pool that did not undergo any treatments prior being sorted, serving as 
a control population. 
 
Scheme S3. Selection of ISRIBRES, ISRIBSEN, AAA1-075B sensitive (075BSEN) 
and AAA1-084 sensitive (084SEN) cells, based on the ISR-activated CHOP::GFP 
fluorescent reporter upon histidinol (HIS) treatment in Eif2b2H188X mutant population. 
 
Cell pools were then expanded, phenotypically characterized and their genomic 
DNA obtained for subsequent next-generation sequencing analysis. Individual clones 
were genotyped following Sanger sequencing of PCR products amplified from 
genomic DNA. 
All cells were washed with PBS once and collected in PBS containing 4 mM 
EDTA and 0.5% BSA and sorted on INFLUX cell sorter. 
 
NGS sequencing of Eif2b2 containing targeted mutations 
Genomic DNA was prepared from 1 x 107 cells using Blood and Cell culture 
Midi Kit (13343, Qiagen). Then two rounds of PCR were performed to isolate 
amplicons for NGS sequencing. The first round of 18 cycles with primers 1975 and 
1976 to amplify a 244 bp region of Eif2b2 from 31 µg of DNA (corresponding to 
genomic DNA from 19,300 cells) divided into 5 PCR reactions of 50 µL using Q5 
polymerase (M0493, NEB) according to the manufacturer’s protocol. The PCR 
reactions were then pooled together and combined with 250 µL of solubilization 
buffer from Gene-Jet gel purification kit (K0691, Thermo Fisher). Thereafter mixes 
were purified following the standard Gene-Jet gel purification protocol (without 
adding the isopropanol recommended for smaller products). The second round used 
11-15 cycles of PCR with a universal Illumina P5 primer (1977) and individually 
barcoded P7 primers for each sample (1762-1768). The resulting products were 
purified as above and quantified using Agilent DNA chip 1000 and qPCR with 
















2B and table S4) or SE50 NGS sequencing (Figure 3B and table S5).  Primers details 
are provided in Table S2). 
The sequencing reads were converted to BAM files aligned to the hamster 
EIF2b2 locus and then corresponding SAM files were aligned to 31 bp templates 
surrounding each mutation: N162 
(NNNGAXGTGATCATGACCATTGGCTATTCT), H188 
(CGAAAGAGGAAGTTCNNNGTCATTGTTGCC) and I190  
(CGAAAGAGGAXGTTXCATGTCNNNGTTGCCS). Reads that differed by less 
than three residues outside the degenerate sequence were counted for codons and 
amino acids at each position using Python scripts. 
 
Electron microscopy 
3 µL aliquots of the protein complex diluted to 2 µM in gel filtration buffer 
were applied on holey carbon grids (Quantifoil 300 mesh R2/2), rendered more 
hydrophilic with a 20 seconds 9:1 argon–oxygen plasma treatment (Fischione Model 
1070). Grids were blotted and flash-frozen in liquid ethane using a Vitrobot mark II 
(Thermo Fisher) with a blotting time of 7s at 10 °C and 100% humidity. Data 
acquisition was performed on a Titan Krios microscope (Thermo Fisher) operated at 
300 kV. The dataset was recorded on a back-thinned Falcon II detector (Thermo 
Fisher) at a calibrated magnification of x 80 000 (resulting in a pixel size of 1.75 Å on 
the object scale) with a defocus range of 2.5-3.5 µm. An in-house built system was 
used to intercept the videos from the detector at a speed of 25 frames for the 1.5 




After visual inspection of the micrographs, 765 images were selected for further 
processing. The movie frames were aligned with MotionCorr (17) for whole-image 
motion correction. Contrast transfer function parameters for the micrographs were 
estimated using Gctf (18). 237,486 particles were selected semi-automatically using 
the e2boxer routine from EMAN2 (19). All 2D and 3D classifications and refinements 
were performed using RELION (20, 21). 
 Reference-free 2D classification (Fig. S3A) was first performed, followed by a 
3D classification step using a low-pass filtered (60 Å) map calculated from the 
tetrameric eIF2B (βδ)2 complex from Chaetomium thermophilum (PDB: 5DBO) . An 
initial map was consistent with the presence of all five subunits in our sample and also 
the existence of C2 symmetry. We subclassified particles into 8 3D classes (Fig. 
S3B). One class representing 17 % of the dataset (41750 particles) was then used for 
3D refinement in C2 symmetry. 
Statistical movie processing was performed as described (22), including 
modelling of the fall-off of high-resolution information content by radiation damage 
in a dose-dependent manner as described (23). The reported overall resolution of 4.1 
Å was calculated using the gold-standard Fourier shell correlation (FSC) 0.143 
criterion (24) (Fig. S3C) and was corrected for the effects of a soft mask on the FSC 





was corrected for the modulation transfer function of the detector and sharpened by 
applying a negative B factor that was estimated using automated procedures (26). 
As a control experiment, data were also processed without applying symmetry (C1). 
This generated a map at 4.2 Å resolution that still contained a density attributable to 
ISRIB in the core of the complex (data not shown). 
 
Model building and refinement 
S. pombe eIF2B structure (PDB accession code: 5B04, (10)) was used as a 
starting model. A poly-alanine (glycines were immediately added to account for 
flexibility) model was generated and subunits were individually fitted to the density 
map in Chimera (27). This model was then finely fitted using real space refinement 
and loops found to be divergent between S. pombe and human were rebuilt in Coot 
(28). All side chains for which density was clearly resolved (up to 37% of non-Ala 
non-Gly residues in α and β subunits and as low as 8% in ε subunits) were positioned. 
The ISRIB molecule was then manually fitted in the density located at the regulatory 
core of eIF2B. 
The model was then refined using phenix.real_space_refine (29) to optimize 
both protein and ligand geometry and limit clashes. Finally, REFMAC in CCP-EM 
(30) was used to further refine the model and automatically generate the map vs. 
model FSC curves (Fig. S3D) and assess overfitting, as described (31). Briefly, the 
procedure involved initial random displacement of the atoms within the final model 
and refinement against one of the two half maps to generate the FSCwork curve. A 
cross-validated FSCfree curve was then calculated between this refined model and the 
other half map. The similarity between FSCwork and  FSCfree curves is indicative of the 
absence of overfitting. Maps were analyzed and visualized using Chimera (27). 
Figures were prepared using Chimera and Pymol (Molecular Graphics System, 
Version 2.0.6 Schrödinger, LLC, http://www.pymol.org). 
Information on structural data processing is summarized in table S6. 
 
 ISRIB analogs chemistry  
Compound design (Scheme S4). To observe ISRIB's interaction with eIF2B 
directly, we designed a fluorescently labeled derivative (AAA2-101) (Fig. S2A) based 
on known structure–activity relationships of ISRIB derivatives (11). These show that 
major modifications of the central trans-cyclohexyl group and the glycolamide 
linkages are poorly tolerated, whereas changes to the terminal aryl groups in some 
cases maintain or enhance activity. Since conservative modifications of the 
glycolamide portions appeared possible (11), we attempted to tether the glycolamide 
Cα of one of the cyclohexyl substituents to the neighboring phenyl in the form of a 
chromane group. We observed that the compound containing this group (AAA1-084, 
Fig. S2A) retained activity and was only 8.5-fold less active than trans-ISRIB (Fig. 
S2B). Molecular modeling (compare (10); Figure 3C therein) suggested that the 
benzylic C of the chromane system would face the solvent-accessible entry into the 
putative ISRIB-binding site of eIF2B. Replacement of the chromane with the 
dihydrobenzoxazine system afforded a compound (AAA1-075B, Fig. S2A) only 3-





was then used to elaborate the fluorescently labeled compound AAA2-101, which 
contains a flexible linker terminating in a 5/6-carboxyfluorescein moiety. 
General. LC-MS analyses were performed using a Shimadzu UFLCXR system 
coupled to an Applied Biosystems API2000 mass spectrometer. The HPLC column 
used was Phenomenex Gemini-NX, 3 µm-110 Å, C18, 50 x 2 mm with a flow rate of 
0.5 mL/min and UV monitoring at 220 and 254 nm. Gradient elution: pre-
equilibration for 1 min at 5% eluant B in eluant A; then 5 to 98% B over 2 min, 98% 
B for 2 min, 98 to 10% B over 0.5 min, then 10% B for one min. Eluant A: 0.1% 
HCOOH in H2O; eluant B: 0.1% HCOOH in MeCN. 1H-NMR spectra were recorded 
using a Bruker-AV 400 instrument operating at 400.13 MHz and 13C-NMR spectra 
were recorded at 101.62 MHz. Chemical shifts (δ) are in parts per million (ppm) with 
reference to solvent chemical shift. High-resolution time-of-flight electrospray (TOF-
ES+) mass spectra (HR-MS) were recorded using a Bruker micrOTOF spectrometer. 
N,N'-((1r,4r)-Cyclohexane-1,4-diyl)bis(2-(4-chlorophenoxy)acetamide) (2a; 
trans-ISRIB). This compound was prepared from trans-1,4-cyclohexanediamine (1a) 
and 4-chlorophenoxyacetyl chloride as described (2). 1H-NMR (DMSO-d6): δ 7.97 (d, 
J = 8.0 Hz, 2H), 7.33 (d, J = 8.8 Hz, 4H), 6.96 (d, J = 8.6 Hz, 4H), 4.44 (s, 4H), 3.58 
(br s, 2H), 1.75 (br d, J = 7.5 Hz, 4H), 1.33 (quint, J = 10.2 Hz, 4H); 13C-NMR 
(DMSO-d6): δ 167, 157, 129, 125, 117, 67, 47, 31; LC-MS: m/z 451.3 [M + H]+; 
HPLC: tR 2.92 min (> 95%). 
N,N'-((1s,4s)-Cyclohexane-1,4-diyl)bis(2-(4-chlorophenoxy)acetamide) (2b; 
cis-ISRIB). This compound was prepared from cis-1,4-cyclohexanediamine (1b) and 
4-chlorophenoxyacetyl chloride as described (2). 1H-NMR (DMSO-d6): δ 7.87 (d, J = 
7.1 Hz, 2H), 7.34 (d, J = 9.5 Hz, 4H), 6.98 (d, J = 8.7 Hz, 4H), 4.49 (s, 4H), 3.73 (br 
s, 2H), 1.54-1.63 (m, 8H); 13C-NMR (DMSO-d6): δ 167, 157, 130, 125, 117, 67, 45, 
28; LC-MS: m/z 451.4 [M + H]+; HPLC: tR 2.96 min (95%). 
N,N'-((1r,4r)-Cyclohexane-1,4-diyl)bis(2-methoxyacetamide) (3; AAA1-
090). A stirred solution of 1a (0.11 g, 1 mmol) and iPr2NEt (0.37 mL, 2.2 mmol) in 
CH2Cl2 (5 mL) was cooled to 0 oC. Methoxyacetyl chloride (0.19 mL, 2.2 mmol) in 
CH2Cl2 (1 mL) was added dropwise. The resulting suspension was stirred at 0 oC for 
30 min and at room temperature for 1 h. EtOAc was added and the solution was 
extracted successively with saturated aq solutions of NH4Cl, NaHCO3, and brine. The 
organic phase was dried with Na2SO4, filtered, and evaporated. The residue was 
triturated with Et2O, collected and dried to afford the title compound as a white 
powder (0.219 g, 85%) 1H-NMR (DMSO-d6): δ 7.55 (d, J = 8.8 Hz, 2H), 3.75 (s, 4H), 
3.55 (br s, 2H), 3.28 (s, 6H), 1.70 (d, J = 8.4 Hz, 4H), 1.33 (quint, J = 19.7 Hz, 4H); 
13C-NMR (DMSO-d6): δ 168, 72, 59, 47, 31; HR-MS: m/z 259.1660 [M + H]+, 
C12H23N2O4 requires 259.1652. 
N-((1r,4r)-4-Aminocyclohexyl)-2-(4-chlorophenoxy)acetamide (4b). A 
stirred solution of tert-butyl ((1r,4r)-4-aminocyclohexyl)carbamate (1c, 2.143 g, 10 
mmol) and iPr2NEt (1.9 mL, 11 mmol) in CH2Cl2 (50 mL) was cooled to 0 oC (ice 
bath). 4-Chlorophenoxyacetyl chloride (1.7 mL, 11 mmol) in CH2Cl2 (3 mL) was 
added dropwise. The resulting suspension was stirred at 0 oC for 30 min and at room 
temperature for 1 h. EtOAc was added and the solution was extracted successively 
with saturated aq solutions of NH4Cl, NaHCO3, and brine. The organic phase was 
dried with Na2SO4, filtered, and evaporated. The residue was triturated with Et2O, 
collected, and dried to afford the Boc-protected intermediate 4a as a white powder 





A suspension of 4a (1.43 g, 3.5 mmol) in dioxane–MeOH (2:1; 6 mL) was 
treated with 4 M HCl in dioxane (7 mL, 28 mmol) with stirring for 2 h. The resulting 
solution was evaporated and the residue was triturated with Et2O, collected, and dried 
to afford the HCl salt of the title compound 4b as a white powder (1.071 g, 96%). 1H-
NMR (DMSO-d6): δ 8.0 (d, J = 6.5 Hz, 1H), 7.33 (d, J = 8.7 Hz, 2H), 6.96 (d, J = 8.7 
Hz, 2H), 5.98 (br s, 2H), 4.46 (s, 2H), 3.50-3.60 (m, 1H), 2.91 (br s, 1H), 1.97, 1.78 
(dd, J = 10.9 Hz, J = 13.1 Hz, 4H), 1.36 (sext, 4H); 13C-NMR (DMSO-d6): δ 167, 
157, 129 , 125 , 117, 67, 49, 47, 31, 29; HPLC: tR 2.03 min (95%).  
6-Chloro-N-((1r,4r)-4-(2-(4-chlorophenoxy)acetamido)cyclohexyl) 
chromane-2-carboxamide (6; AAA1-084). To a stirred solution of (rac)-6-
chlorochromane-2-carboxylic acid (5; 0.1 g, 0.5 mmol; prepared as described (32)) 
and Et3N (0.13 mL, 1 mmol) in CH2Cl2 (5 mL) was added O-(benzotriazol-1-yl)-
N,N,N’,N’-tetramethyluronium hexafluorophosphate (HBTU; 0.21 g, 0.6 mmol). The 
mixture was stirred for 10 min, when 4b (0.16 g, 0.55 mmol) was added. Stirring was 
continued overnight, the reaction was diluted with H2O, and was extracted with 
EtOAc. The organic layer was washed with aq NH4Cl and brine, dried over Na2SO4, 
filtered, and evaporated. The residue was triturated with Et2O, collected, and dried to 
afford the title compound as an off-white powder (0.155 g, 65%). 1H-NMR (DMSO-
d6): δ 7.95 (d, J = 8.2 Hz, 1H), 7.83 (d, J = 7.5 Hz, 1H), 7.35 (d, J = 8.3, 2H), 7.14 (d, 
J = 7.2, 2H), 6.97 (d, J = 9.3, 2H), 6.89 (d, J = 9.0 Hz, 1H), 4.51, 4.49 (dd, J = 3.9 Hz, 
J = 3.0 Hz, 1H), 4.46 (s, 2H), 3.59 (br s, 2H), 2.84-2.76 (m, 1H), 2.72-2.65 (m, 1H), 
2.17-2.10 (m, 1H), 1.90-1.82 (m, 1H), 1.78 (br s, 4H), 1.40-1.30 (m, 4H); 13C-NMR 
(DMSO-d6): δ 169, 168, 157, 152, 129, 126, 125, 124, 118, 117, 75, 67, 48, 31, 25, 
23; HPLC: tR 3.01 min (95%). HR-MS: m/z 477.1350 [M + H]+, C24H27Cl2N2O4 
requires 477.1342. 
6-Chloro-N-((1r,4r)-4-(2-(4-chlorophenoxy)acetamido)cyclohexyl)-3,4-
dihydro-2H-benzo[b][1,4]oxazine-2-carboxamide (8a; AAA1-075B). A solution of 
(rac)-ethyl 6-chloro-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylate (7a; 0.25 g, 1 
mmol; prepared as described (33)) in THF–H2O (2:1) was treated with LiOH.H2O 
(0.12 g, 3 mmol) and the resulting mixture was stirred for 3 h. The solution was 
neutralized with 1 M aq HCl solution and extracted with EtOAc. The organic phase 
was dried over Na2SO4, filtered and concentrated to afford 6-chloro-3,4-dihydro-2H-
1,4-benzoxazine-2-carboxylic acid 7b (0.19 g, 89%). 
To a stirred solution of 7b (0.15 g, 0.7 mmol) and Et3N (0.18 mL, 1.4 mmol) in 
CH2Cl2 (5 mL) was added HBTU (0.3 g, 0.84 mmol). The mixture was stirred for 10 
min, when 4b (0.23 g, 0.77 mmol) was added. Stirring was continued overnight, the 
reaction was diluted with H2O, and was extracted with EtOAc. The organic layer was 
washed with aq NH4Cl and brine, dried over Na2SO4, filtered, and evaporated. The 
residue was dissolved in MeOH (1 mL) and the product was precipitated by addition 
of excess Et2O. The precipitate was collected, washed with more Et2O and dried to 
afford the title compound as an off-white powder (0.224 g, 67%). 1H-NMR (DMSO-
d6): δ 8.08 (d, J = 8.4 Hz, 1H), 7.92 (d, J = 8.4 Hz, 1H), 7.34 (d, J = 8.7 Hz, 2H), 6.97 
(d, J = 9.0 Hz, 2H), 6.78 (d, J = 8.4 Hz, 1H), 6.63 (d, J = 2.7 Hz, 1H), 6.50, 6.48 (dd, 
J = 3.3 Hz, J = 2.7 Hz, 1H), 6.31 (s, 1H), 4.47 (s, 2H), 4.44 (dd, J = 3.3 Hz, J =3.6 
Hz, 1H), 3.57 (br s, 2H), 3.45, 3.42 (tt, J = 6.7 Hz, J = 6.2 Hz, 1H), 3.20-3.15 (m, 
1H), 1.78-1.70 (m, 4H), 1.42-1.29 (m, 4H); 13C-NMR (DMSO-d6): δ 168, 166, 157, 
141, 136, 129, 125, 118, 116, 114, 73, 68, 48, 42, 31; HPLC: tR 2.90 min (95%). HR-





4- and 5-((2-(2-(2-(2-(6-Chloro-2-(((1r,4r)-4-(2-(4-chlorophenoxy) 
acetamido)cyclohexyl)carbamoyl)-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-
yl)acetamido)ethoxy)ethoxy)ethyl)carbamoyl)-2-(6-hydroxy-3-oxo-3H-xanthen-
9-yl)benzoic acid (8f; AAA2-101). To a solution of 8a (0.19 g, 0.4 mmol) in DMF (5 
mL) was added K2CO3 (0.18 g, 1.2 mmol), NaI (0.09 g, 0.6 mmol), and methyl 
bromoacetate (0.1 mL, 0.48 mmol). The mixture was stirred at 125 oC for 16 h, 
cooled to room temperature, and diluted with H2O (10 mL). The solution was 
extracted with EtOAc and the organic phase was washed with H2O and brine, dried 
over Na2SO4, filtered, and evaporated. The residue was purified by silica gel column 
chromatography (CH2Cl2–THF gradient elution) to afford methyl ester 8b (0.14 g, 
65%). 
A solution of 8b (0.1 g, 0.18 mmol) in THF–H2O (2:1) was treated with 
LiOH.H2O (0.037 g, 0.9 mmol) and the resulting mixture was stirred for 3 h. The 
reaction was neutralized with 1 M aq HCl and extracted with EtOAc. The organic 
phase was dried over Na2SO4, filtered, and evaporated to afford the carboxylic acid 
derivative 8c (0.09 g, 98%). 
8c (0.09 g, 0.2 mmol) and Et3N (0.06 mL, 0.5 mmol) were dissolved in CH2Cl2 
(3 mL). HBTU (0.08 g, 0.22 mmol) was added and the mixture was stirred for 10 min, 
when tert-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (0.054 g, 0.22 mmol) 
in CH2Cl2 (1 mL) was added. The mixture was stirred overnight, diluted with H2O, 
and extracted with EtOAc. The organic phase was washed with aq NH4Cl and brine, 
dried over Na2SO4, filtered, and evaporated. The residue was purified by silica gel 
column chromatography (CH2Cl2–MeOH gradient elution) to afford the Boc-
protected intermediate 8d (0.12 g, 80%). 
A solution of 8d (0.12 g, 0.15 mmol) in dioxane (0.5 mL) was treated with 4 M 
HCl in dioxane (1 mL, 4 mmol). After stirring for 2 h the solution was evaporated. 
The residue was dissolved in MeOH (0.5 mL) and the product was precipitated by 
addition of excess Et2O. The precipitate was collected and dried to afford the HCl salt 
of the amine derivative 8e (0.10 g, 98%). 
8c (14 mg, 0.02 mmol) and 5-(and 6-) carboxyfluorescein succinimidyl ester 
(9.4 mg, 0.02 mmol; NHS-fluorescein, 5/6-carboxyfluorescein succinimidyl ester 
mixed isomer (46410, ThermoFisher Scientific)), were dissolved in DMF (1 mL) with 
Et3N (4 µL). The mixture was stirred overnight at 31 oC and was evaporated. The 
residue was fractionated by semi-preparative HPLC (Phenomenex Gemini 5 µm-110 
Å, C18, 150 x 10 mm column; 5 mL/min flow rate) with linear gradient elution of 
H2O–MeCN (containing 0.1% HCOOH) from 85:15 to 5:95 over 13 min to afford the 
title compound 8f as an orange powder (0.015 g, 75%). 1H-NMR (DMSO-d6): δ 8.88, 
8.74 (tt, J = 5.8 Hz, J = 11.7 Hz, 1H), 8.46 (s, 1H), 8.30 (br s, 1H), 8.22, 8.15 (dd, J = 
8.6 Hz, J = 8.0 Hz, 1H), 8.05-8.11 (m, 1H), 7.96 (t, J = 8.1 Hz, 2H), 7.68 (s, 1H), 7.34 
(t, J = 9.7 Hz, 2H), 6.95 (d, J = 8.6 Hz, 2H), 6.82 (d, J = 8.6 Hz, 1H), 6.67 (s, 2H), 
6.58 (d, J = 8.9 Hz, 2H), 6.54 (s, 2H), 6.49 (d, J = 8.0 Hz, 1H), 4.61 (quint, J = 4.0 
Hz, 1H), 4.44 (s, 2H), 4.44, 3.81-3.96 (m, 4H), 3.5-3.57 (m, 8H), 2.07 (s, 2H), 1.67-
1.78 (m, 4H), 1.29-1.39 (m, 4H), 1.23 (s, 4H); HPLC: tR 2.81 min (95%); HR-MS: 






   
  
Scheme S4. (a) 1a or 1b, 4-chlorophenoxyacetyl chloride, iPr2NEt, CH2Cl2, 0 oC to rt 
(70-88%); (b) 1a, methoxyacetyl chloride, iPr2NEt, CH2Cl2, 0 oC to rt (85%); (c) 1c, 
4-chlorophenoxyacetyl chloride, iPr2NEt, CH2Cl2, 0 oC to rt (95%); (d, f, and k) 4 M 
HCl in dioxane–MeOH (89-98%); (e) 4b and 5, HBTU, Et3N, CH2Cl2 (65%); (g) 4b 
and 7b, HBTU, Et3N, CH2Cl2 (67%); (h) methyl bromoacetate, K2CO3, NaI, DMF, 
125 oC, 16 h (65%); (i) LiOH, THF–H2O (98%); (j) tert-butyl (2-(2-(2-
aminoethoxy)ethoxy)ethyl)carbamate, HBTU, Et3N, CH2Cl2 (80%); (l) 5-(and 6-) 








Biochemical analysis of human eIF2B 
(A) Chromatogram of endogenous human eIF2B purified from HeLa cells with 
3xFLAG-tag (introduced by homologous recombination into the EIF2B2 locus), 
resolved by size exclusion chromatography on a SEC-3 300 Å chromatography 
column (left panel). The indicated fractions were analyzed on a Coomassie-stained 
SDS-PAGE gel (right panel, the asterisks * indicates PRMT5 – a contaminant) and 
used in structural analysis. 
(B) Immunoblot of 3xFLAG-tagged eIF2Bβ detected with anti-FLAG M2 antibodies 
in HeLa cell lysates that were either treated with DMSO (top panel) or ISRIB (200 
nM) (bottom panel) and resolved on a 5-20% sucrose density gradient.  The observed 
shift of 3xFLAG-eIF2Bβ signal towards HMW fractions reflects the stabilizing effect 
of ISRIB on the protein complex (compare top and bottom panels) (performed once, 
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ISRIB and its analogs inhibit the ISR in cells and bind eIF2B in vitro 
(A) Structures of ISRIB and ISRIB analogs used in this study: active trans-ISRIB, cis-
ISRIB, the reference analogs AAA1-075B and AAA1-084, the inactive AAA1-090 
and fluorescein-labeled AAA2-101 used in the fluorescence polarization experiments. 
(B) Plot of the inhibition of the Integrated Stress Response (ISR) activated 
CHOP::GFP signal, induced upon treatment of CHO-K1 cells with histidinol (HIS) 
(0.5 mM), in the presence of escalating concentrations of trans and cis-ISRIB. Shown 
is a representative from three independent experiments conducted for trans and cis-
ISRIB and of single experiment conducted for analogs. Concentration of inhibitor is 
represented on a log10 scale. Curve fitting and EC50 was generated using agonist vs. 
response function on GraphPad Prism. 
(C) Plot of the FP signal arising from samples with fluorescein-labeled AAA2-101 
(100 nM) bound to purified human eIF2B (250 nM) in the presence of the indicated 
concentration of unlabeled ISRIB analogs introduced as competitors. Shown is a 
representative from three independent experiments. Concentration of inhibitor is 
represented on a log10 scale. Curve fitting and EC50 was generated using agonist vs. 
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Cryo-electron microscopy data processing 
(A) Representative sample of the reference-free 2D class averages of eIF2B particles 
used for 3D classification and initial model generation. Analysis was performed using 
RELION and EMAN2 software. 
(B) After 3D classification was conducted on the whole particle dataset (237,213), 
17% (40,326 particles) were used to generate and refine the final 3D map. Analysis 
was performed using RELION. 
(C) Gold-standard Fourier shell correlation (FSC) curves. Unmasked map FSC curve 
is represented in black. Masked-corrected map FSC curve is represented in grey and 
crosses the 0.143 ‘gold standard’ purple line at a resolution of 4.1 Å indicating the 
resolution of the masked map. 
(D) Refinement and cross-validation of the eIF2B model. The final map vs. model 
‘FSC average’ curve is represented in black. For cross-validation, the model was 
‘shaken’ (see Methods section) and refined against one of the two half-maps to 
generate the ‘FSC work’ curve (grey line).  The ‘FSC free’ curve was calculated 
between this same refined model and the other half-map (blue line). Superimposition 
of the two FSC curves shows no sign of over-fitting. 
(E) Transparent representations of the “soft” mask used for post-processing of the 




































































Structure of the ISRIB-bound human eIF2B 
(A) Density map colored according to local resolution for the ISRIB-bound eIF2B 
complex. The highest resolution is at the core of the (βδ)2 dimer interface, where the 
putative density of ISRIB was detected. The red-blue palette covers resolution range 
from 3.7 Å to >6.55 Å. 
(B) Representative density depicted as a mesh around the eIF2B atomic model 
including well-resolved side chains from the core of (βδ)2 dimer interface. Individual 
residues of β (blue) and δ (green) subunits are labeled for reference. 
(C) Left: cryo-EM map of human eIF2B bound to ISRIB (“central” view). The ISRIB 
density is shown in orange. Right: close up of the “central” view showing density 
corresponding to ISRIB at the (βδ)2 dimer interface, without and with the 
superimposed model. Residues contacting ISRIB in the central part of the pocket from 
the β (blue) and δ (green) subunits are indicated. ISRIB is represented as orange 
sticks. 
(D) Close-up of the hydrophobic end of the pocket. Two views of the eIF2B complex 
core are presented, showing the symmetrically opposite sides of the pocket. The left 
panel view is from the solvent area looking at the core of the protein. The right panel 
is from the core looking at the solvent area. 
(E) Superimposition of ISRIB-bound human (cyan) and yeast eIF2B (lacking bound 








Individual clones from 084SEN pool recapitulate the variation in sensitivity to ISRIB 
and AAA1-084 observed in ISRIBRES pool of Eif2b2H188X 
(A) Traces of dye-termination sequencing reactions of PCR amplified Eif2b2 exon 3 
from indicated cell clones: A1 (parental, wt), A3 (H188S/T), A5 (H188M), B3 
(H188K/Δ). H188 is highlighted. 
(B) Graphs showing inhibition of the ISR-activated CHOP::GFP signal, induced upon 
treatment with HIS (0.5 mM), by ISRIB and AAA1-084 (084) in individual clones 
from 084SEN pool (from Figure 3B). Shown is data from three independent 
experiments for each of the compounds. Concentration of ISRIB is represented on a 
log10 scale. Curves fitting and EC50 was generated using agonist vs. response function 
on GraphPad Prism. 
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Biochemical characterization of purified hamster eIF2B 
Coomassie stained SDS-PAGE gel of endogenous hamster eIF2B purified from 
wildtype (wt, clone A1), Eif2b2H188K (clone B3) and Eif2b4L180F (clone S9) CHO cells 




















Table S1. Cell lines 
 
 
Table S2. Oligonucleotide list	
	
	
Table S3. Plasmid list	
	
  
Gene Exon Cells Clone	name Description Mutagenized	region	(number	shows	amino	
acid	position	at	which	mutagenesis	occurred)




Eif2b2 3 CHO-K1 N162X mixed	population	of	ISRIB-resistant	cells 162_XEVIMTIGYSRTVEAFLKEAARKRKFHVIV
Eif2b2 3 CHO-K1 H188X mixed	population	of	ISRIB-resistant	cells 188_XVIVAECAPFCQVRG
Eif2b2 3 CHO-K1 I190X mixed	population	of	ISRIB-resistant	cells 190_XVAECAPFCQVRG
Eif2b2 3 CHO-K1 H188X-075B mixed	population	of	075B-sensitive	cells 188_XVIVAECAPFCQVRG
Eif2b2 3 CHO-K1 H188X-084 mixed	population	of	084-sensitive	cells 188_XVIVAECAPFCQVRG




Eif2b2 3 CHO-K1 A5 H188M,	homozygous,	084-sensitive,	
strongly	ISRIB-resistant
188_MVIVAECAPFCQVRG
Eif2b2 3 CHO-K1 B3 H188K/Δ,	heterozygous,	084-sensitive,	strongly	ISRIB-resistant 188_KVIVAECAPFCQVRG
































































































Oligo1777 P5_Truseq	Universal_1977	 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT adaptor	primer	for	NGS 2B,	3B













Table S4. Allele frequency (Fig. 2B) 
 
 






Reads Reads %	Reads Reads %	Reads Reads
%	
Reads Reads %	Reads Reads %	Reads
* 855 0.20 6575 1.74 1025 0.31 6215 2.48 340 0.09 3467 1.23
A 3953 0.92 1768 0.47 2248 0.69 4305 1.72 1106 0.31 1213 0.43
C 2429 0.57 1654 0.44 5992 1.83 716 0.29 1416 0.39 3145 1.12
D 3953 0.92 1436 0.38 662 0.20 5075 2.03 419 0.12 5912 2.10
E 2655 0.62 867 0.23 227 0.07 8902 3.55 426 0.12 574 0.20
F 2064 0.48 2798 0.74 8730 2.66 682 0.27 3363 0.93 10199 3.62
G 419 0.10 26632 7.05 965 0.29 52762 21.05 949 0.26 5716 2.03
H 9410 2.20 10487 2.78 269253 82.06 6443 2.57 208 0.06 1315 0.47
I 2804 0.66 14912 3.95 4980 1.52 1749 0.70 326077 90.10 39307 13.96
K 3520 0.82 2809 0.74 499 0.15 20494 8.18 139 0.04 359 0.13
L 10772 2.52 7055 1.87 1794 0.55 46099 18.39 8405 2.32 5827 2.07
M 1211 0.28 724 0.19 350 0.11 4795 1.91 192 0.05 68523 24.34
N 350813 82.08 165829 43.92 3058 0.93 668 0.27 398 0.11 770 0.27
P 2485 0.58 11242 2.98 425 0.13 648 0.26 331 0.09 947 0.34
Q 5727 1.34 1589 0.42 443 0.14 15550 6.21 207 0.06 2403 0.85
R 7597 1.78 8707 2.31 411 0.13 59827 23.87 548 0.15 2188 0.78
S 8007 1.87 9712 2.57 2208 0.67 8331 3.32 829 0.23 4443 1.58
T 2143 0.50 99150 26.26 1737 0.53 3153 1.26 452 0.12 1932 0.69
V 1721 0.40 2101 0.56 13035 3.97 2950 1.18 15627 4.32 1749 0.62
W 428 0.10 142 0.04 4038 1.23 618 0.25 147 0.04 79154 28.11
X 253 0.06 209 0.06 329 0.10 256 0.10 63 0.02 48 0.02
Y 4159 0.97 1146 0.30 5704 1.74 379 0.15 262 0.07 42391 15.05
Total	




ISRIB-SEN ISRIB-RES ISRIB-SEN ISRIB-RES ISRIB-SEN ISRIB-RES
Reads %	Reads Reads %	Reads Reads %	Reads Reads %	Reads
* 8309 2.64 648 0.22 4001 1.88 4428 1.63
A 5809 1.85 4595 1.56 16814 7.89 23876 8.78
C 1346 0.43 3465 1.17 1687 0.79 2635 0.97
D 4608 1.47 797 0.27 2338 1.10 3892 1.43
E 8292 2.64 920 0.31 1228 0.58 1311 0.48
F 1776 0.57 12004 4.06 2450 1.15 3853 1.42
G 52131 16.59 1558 0.53 10887 5.11 12264 4.51
H 9311 2.96 226030 76.53 34473 16.18 55443 20.40
I 2684 0.85 4081 1.38 3612 1.70 4906 1.81
K 27535 8.76 803 0.27 47373 22.24 44470 16.36
L 67765 21.56 6498 2.20 13552 6.36 12728 4.68
M 6690 2.13 666 0.23 11051 5.19 8943 3.29
N 772 0.25 1915 0.65 1587 0.75 1816 0.67
P 1193 0.38 1520 0.52 1038 0.49 1298 0.48
Q 22530 7.17 1111 0.38 4152 1.95 6029 2.22
R 71454 22.74 1397 0.47 6097 2.86 7651 2.82
S 11841 3.77 4824 1.63 31921 14.98 49558 18.23
T 4857 1.55 3513 1.19 11650 5.47 15931 5.86
V 3537 1.13 11438 3.87 5317 2.50 7625 2.81
W 1177 0.37 4767 1.61 1123 0.53 2019 0.74
X 61 0.02 61 0.02 48 0.02 56 0.02
Y 613 0.20 2757 0.93 654 0.31 1105 0.41
Total	
Reads 314291 295368 213053 271837
H188X	ISRIB-RES
Amino	












































1 FSCaverage = Σ(Nshell FSCshell / Σ(Nshell), where FSCshell is the FSC 
in a given shell, Nshell is the number of ‘structure factors’ in the 
shell. FSCshell = Σ(Fmodel FEM)/(√(Σ(|F|2 model)) √(Σ(F2 EM)). 
